RS105304A - Methods of treating angiogenesis,tumor growth,and metastasis - Google Patents

Methods of treating angiogenesis,tumor growth,and metastasis

Info

Publication number
RS105304A
RS105304A YUP-1053/04A YUP105304A RS105304A RS 105304 A RS105304 A RS 105304A YU P105304 A YUP105304 A YU P105304A RS 105304 A RS105304 A RS 105304A
Authority
RS
Serbia
Prior art keywords
metastasis
methods
tumor growth
treating angiogenesis
patient
Prior art date
Application number
YUP-1053/04A
Other languages
English (en)
Inventor
Leo Otterbein
Augustine Choi
Original Assignee
Yale University,
University Of Pittsburgh Of The Commonwealth System Of Higher Education,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University,, University Of Pittsburgh Of The Commonwealth System Of Higher Education, filed Critical Yale University,
Publication of RS105304A publication Critical patent/RS105304A/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Predmetni pronalazak se odnosi na postupak za lečenje kancera ili neželjene angiogeneze kod pacijenta, koji obuhvata primenu na pacijentu farmaceutskog preparata koji sadrži ugljen monoksid.
YUP-1053/04A 2002-06-05 2003-06-05 Methods of treating angiogenesis,tumor growth,and metastasis RS105304A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38656102P 2002-06-05 2002-06-05
PCT/US2003/017731 WO2003103585A2 (en) 2002-06-05 2003-06-05 Methods of treating angiogenesis, tumor growth, and metastasis

Publications (1)

Publication Number Publication Date
RS105304A true RS105304A (en) 2007-02-05

Family

ID=29736179

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-1053/04A RS105304A (en) 2002-06-05 2003-06-05 Methods of treating angiogenesis,tumor growth,and metastasis

Country Status (14)

Country Link
US (1) US20040258772A1 (sr)
EP (1) EP1509237A4 (sr)
JP (1) JP2005532351A (sr)
CN (1) CN1674922A (sr)
AU (1) AU2003248621A1 (sr)
CA (1) CA2487413A1 (sr)
EA (1) EA200401622A1 (sr)
HR (1) HRP20041146A2 (sr)
MX (1) MXPA04012167A (sr)
NO (1) NO20045354L (sr)
PL (1) PL374375A1 (sr)
RS (1) RS105304A (sr)
UA (1) UA87438C2 (sr)
WO (1) WO2003103585A2 (sr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
HUP0400371A3 (en) * 2001-06-21 2010-06-28 Beth Israel Hospital Use of carbon monoxide for preparation of pharmaceutical composition available for improving survival or function of organ following transplantation
US7011854B2 (en) 2002-02-04 2006-03-14 Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
EP1499186A4 (en) 2002-04-15 2009-10-28 Beth Israel Hospital USE OF HEM-OXYGENASE-1 AND HEM-DEGRADABLE PRODUCTS
CA2481786A1 (en) * 2002-04-15 2003-10-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating necrotizing enterocolitis
CA2481972A1 (en) * 2002-04-15 2003-10-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating ileus
DK1505990T3 (da) * 2002-05-17 2011-11-21 Univ Yale Fremgangsmåder til behandling af hepatitis
EP1515753A4 (en) * 2002-06-21 2009-07-15 Univ Pittsburgh PHARMACEUTICAL USE OF NITROGEN MONOXIDE, HEME OXYGENASE-1 AND HEME DEGRADATION PRODUCTS
DE10230165A1 (de) * 2002-07-04 2004-01-15 Ino Therapeutics Gmbh Verfahren und Vorrichtung zur Administration von Kohlenmonoxid
US20100158795A1 (en) * 2008-06-12 2010-06-24 Pulmonx Methods and systems for assessing lung function and delivering therapeutic agents
CA2504604A1 (en) * 2002-11-07 2004-05-27 Timothy R. Billiar Treatment for hemorrhagic shock
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
AU2004262976A1 (en) * 2003-08-04 2005-02-17 Hemocorm Limited Use of boranocarbonates for the therapeutic delivery of carbon monoxide
CN100475275C (zh) * 2004-01-05 2009-04-08 董永华 肿瘤血管栓塞剂及其储存和释放装置
WO2007073226A1 (en) * 2005-12-20 2007-06-28 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda Method for treating a mammal by administration of a compound having the ability to release co
WO2007073005A1 (ja) * 2005-12-22 2007-06-28 Keio University メチル基転移反応調節物質
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
JP5552262B2 (ja) * 2009-05-13 2014-07-16 フクダ電子株式会社 肺疾患の治療に用いられる気体製剤
CN103491783A (zh) 2011-01-14 2014-01-01 洛杉矶儿童医院 用于治疗包括镰状细胞疾病的疾病的一氧化碳溶液
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
JP6134710B2 (ja) 2011-07-21 2017-05-24 アルファーマ インコーポレイテッドＡｌｆａｍａ，Ｉｎｃ． 一酸化ルテニウム放出分子およびその使用
CA2844660A1 (en) * 2011-08-09 2013-02-14 Leo E. Otterbein Methods of treating dna damage
JPWO2018225785A1 (ja) * 2017-06-06 2020-04-16 株式会社Ａｔｏｍｉｓ ワクチン組成物
AU2020393170A1 (en) 2019-11-25 2022-07-14 Beyond Air, Inc. System and method for delivery of gas to a tissue
US20230346831A1 (en) * 2020-07-16 2023-11-02 Cornell University Methods for treating metastatic cancer using low dose carbon monoxide

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053590A (en) * 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
US4264739A (en) * 1979-01-05 1981-04-28 Merck & Co., Inc. Sparger for cell culture system
US5240912A (en) * 1983-05-09 1993-08-31 Todaro George J Transforming growth factor (TGF) peptides
US5084380A (en) * 1985-01-29 1992-01-28 Applied Biotechnology Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
US5449665A (en) * 1985-09-24 1995-09-12 Item Development Aktiebolag Continuous intravenous infusion of adenosine to human patients undergoing percutaneous transluminal angioplasty
DE3739650C1 (de) * 1987-11-23 1989-05-24 Immuno Ag Fermenter zum Zuechten von Zellkulturen
US5180366A (en) * 1990-10-10 1993-01-19 Woods W T Apparatus and method for angioplasty and for preventing re-stenosis
US5792325A (en) * 1990-11-15 1998-08-11 Richardson, Jr.; William H. Electric arc material processing system
US5293875A (en) * 1992-06-16 1994-03-15 Natus Medical Incorporated In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods
WO1994018954A1 (en) * 1993-02-22 1994-09-01 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of biologics and compositions useful therefor
US5763431A (en) * 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
DE4421433C1 (de) * 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung
US5476764A (en) * 1994-09-16 1995-12-19 The Regents Of The University Of California Method using CO for extending the useful shelf-life of refrigerated red blood cells
US6066333A (en) * 1994-09-22 2000-05-23 William Harvey Research Limited Pharmaceutical control of inflammation
US5664563A (en) * 1994-12-09 1997-09-09 Cardiopulmonary Corporation Pneumatic system
US5914316A (en) * 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
FR2735382B1 (fr) * 1995-06-15 1997-07-25 Air Liquide Installation de production de monoxyde de carbone incorporant une unite de separation cryogenique
US5731326A (en) * 1995-06-30 1998-03-24 Zymogenetics, Inc. PDGF antagonists II
ES2267141T3 (es) * 1996-04-05 2007-03-01 The General Hospital Corporation Tratamiento de una hemoglobinopatia.
US6069132A (en) * 1996-08-14 2000-05-30 Revanker; Ganapathi R. Phosphazole compounds
US6316403B1 (en) * 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
KR100712573B1 (ko) * 1998-03-16 2007-05-02 셀진 코포레이션 염증성 사이토카인 억제제용 2-(2,6-디옥소피페리딘-3-일)이소인돌린 유도체, 그 제조방법 및 그 용도
US6203991B1 (en) * 1998-08-21 2001-03-20 The Regents Of The University Of Michigan Inhibition of smooth muscle cell migration by heme oxygenase I
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US20050250688A1 (en) * 1999-04-01 2005-11-10 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US7632803B2 (en) * 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
BR0208012A (pt) * 2001-03-20 2004-03-02 Glaxo Group Ltd Usos de pelo menos duas drogas e um propelente hfa e de pelo menos uma composição farmaceêutica, e, inalador acondicionado para tratar asma
JP2004526739A (ja) * 2001-03-30 2004-09-02 サングスタット メディカル コーポレイション 血管の、炎症性の及び免疫の障害の治療のための、一酸化炭素生成性化合物
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
DE60202677T2 (de) * 2001-05-25 2005-12-29 Medtronic, Inc., Minneapolis Implantierbare medizinische vorrichtung mit kontrollierter freigabe von gasförmigen mitteln
HUP0400371A3 (en) * 2001-06-21 2010-06-28 Beth Israel Hospital Use of carbon monoxide for preparation of pharmaceutical composition available for improving survival or function of organ following transplantation
US7069026B2 (en) * 2001-06-28 2006-06-27 Nokia Corporation Geographic area assisted system selection for mobile stations
US7011854B2 (en) * 2002-02-04 2006-03-14 Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof
SG148850A1 (en) * 2002-02-13 2009-01-29 Beth Israel Hospital Methods of treating vascular disease
CA2481972A1 (en) * 2002-04-15 2003-10-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating ileus
CA2481786A1 (en) * 2002-04-15 2003-10-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating necrotizing enterocolitis
DK1505990T3 (da) * 2002-05-17 2011-11-21 Univ Yale Fremgangsmåder til behandling af hepatitis
EP1515753A4 (en) * 2002-06-21 2009-07-15 Univ Pittsburgh PHARMACEUTICAL USE OF NITROGEN MONOXIDE, HEME OXYGENASE-1 AND HEME DEGRADATION PRODUCTS
CA2504604A1 (en) * 2002-11-07 2004-05-27 Timothy R. Billiar Treatment for hemorrhagic shock

Also Published As

Publication number Publication date
EP1509237A2 (en) 2005-03-02
MXPA04012167A (es) 2005-09-21
UA87438C2 (ru) 2009-07-27
EA200401622A1 (ru) 2005-06-30
US20040258772A1 (en) 2004-12-23
EP1509237A4 (en) 2006-07-12
WO2003103585A3 (en) 2004-08-26
CA2487413A1 (en) 2003-12-18
CN1674922A (zh) 2005-09-28
WO2003103585A2 (en) 2003-12-18
HRP20041146A2 (en) 2005-06-30
AU2003248621A1 (en) 2003-12-22
PL374375A1 (en) 2005-10-17
NO20045354L (no) 2004-12-22
JP2005532351A (ja) 2005-10-27

Similar Documents

Publication Publication Date Title
RS105304A (en) Methods of treating angiogenesis,tumor growth,and metastasis
HRP20041071A2 (en) Methods of treating hepatitis
RS91004A (en) Methods of treating ileus
IL280818B (en) A methods of producing alpha-galactosidase preparations
MX349188B (es) Sns - 595 y metodos para utilizar el mismo.
HK1217103A1 (zh) 二芳基乙內酰脲化合物
HK1120427A1 (en) Anti-glypican-3 antibody
UA86570C2 (ru) Способ лечения некротизирующего энтероколита
RS20050344A (en) Treatment for hemorrhagic shock
MY150237A (en) Cripto blocking antibodies and uses thereof
MY151032A (en) Treatment of tnf? related disorders
CA2301032A1 (en) A method of preventing or treating estrogen-dependent diseases and disorders
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
AU2003229876A1 (en) Tumour associated antigens
TW200509925A (en) Method comprising irinotecan for treatment of breast cancer
DE60335535D1 (de) Zusammensetzung und verfahren zur abtötung von tumoren
WO2003006657A3 (de) Genregulatorische elemente zur gentherapie, zur prävention und diagnose von metastasen und zur gentherapie von tumoren
TW200614997A (en) Leaf juice of plectranthus amboinicus for treating cancer and/or tumor
MXPA02001238A (es) Uso de la hidralazina y procanaimida en el tratamiento de cancer como reactivadores de la expresion de genes supresores de tumores.